ClinicalTrials.gg
RecruitingNCT07144319ENAiBLEUpdated Oct 29, 2026

Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy

An observational study in Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by Photocure. Recruiting at 12 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Primary conditionNon-Muscle Invasive Bladder NeoplasmsRegistry: Urinary Bladder NeoplasmsReclassifiedWhy we changed it
Registry
Urinary Bladder Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Non-Muscle Invasive Bladder Neoplasms
Why
  1. The study's listed conditions name Non-Muscle Invasive Bladder Neoplasms, a narrower term within Urinary Bladder Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Photocure · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Oct 29, 2026Site recruiting status changed4 sites addedGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Study summary

Blue light cystoscopy (BLC) is a diagnostic procedure in bladder cancer where the inside of the bladder is observed with a camera to detect bladder lesions. Unlike regular white light cystoscopy, blue light cystoscopy makes use of a drug that induces fluorescence under blue light preferentially in neoplastic and malignant cells that helps visualize bladder lesions during the cystoscopic procedure. Blue light cystoscopy has shown to improve detection of bladder cancer.

Cystoscopy, including blue light cystoscopy, is a procedure involving assessment of the visual appearance of the bladder surface, leading to decisions of taking biopsies, remove suspicious areas and assign treatment options. The assessment is subjective and has a large operator variability. These shortcomings show an opportunity for computer aided detection (CADe) medical device to add value to both clinicians and patients.

The objective of this data collection study is to build a high-quality, diverse data set of video, image recordings and relevant clinical data from BLC procedures performed as part of routine clinical practice to train a computer-aided detection (CADe) algorithm for real- time lesion detection during cystoscopy. The data will be used to support the training, non-clinical technical development and testing of such AI algorithms for use during cystoscopy and to provide documentation needed for training of such algorithms and to assist in guiding future validation of such algorithms.

Exploratory purposes of the study is to use data to explore future AI algorithms in bladder cancer, such as computer-aided diagnosis (CADx) AI algorithms, image enhancement and cystoscopy improvement algorithms, including bladder mapping, tumor visualization, cystoscopy documentation, and combination models of image and clinical data including risk assessment, clinical outcomes, and disease modeling

02

Conditions studied

  • Bladder Cancer
  • Non-muscle Invasive Bladder Cancer

Browse trials for

Keywords

  • bladder cancer
  • artificial intelligence
  • cystoscopy
03

In context

Non-Muscle Invasive Bladder Neoplasms Reclassified

294 studies on the registry are indexed under Non-Muscle Invasive Bladder Neoplasms; 126 are open to participants now.

This study's planned enrollment of 500 is above the median of 300 across 49 observational studies indexed under Non-Muscle Invasive Bladder Neoplasms.

Browse Non-Muscle Invasive Bladder Neoplasms studies →

Lead sponsor

Photocure is the lead sponsor of 23 studies on the registry; 2 are open to participants now.

Compared within Non-Muscle Invasive Bladder Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Bladder Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Routine clinical practice patients scheduled for BLC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Written , approved by relevant IRB/IEC, signed
  • Hexvix/Cysview has been prescribed in the usual manner in accordance with the terms of the marketing authorization (see Appendix B)
  • Physician has planned to do a blue light cystoscopy on the patient and to obtain , if clinically indicated, of suspicious lesions with video confirmation.
  • Patient has not previously taken part in this study

Exclusion criteria

Exclusion Criteria:

  • None
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • BLC patients

    Adult, consenting patients scheduled for BLC as part of clinical practice.

06

What researchers measure

Primary outcomes

  1. Video and image collection

    To collect videos, images and relevant clinical data from BLC procedures performed as part of clinical practice. The data will be used to explore the potential of a BLC-enabled AI algorithm for lesion detection of bladder cancer.

    Time frame: 1 day

07

Study locations

12 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Sites
4 sites added. Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum is now Recruiting
Show 4 added (2 United States, 2 Germany)
  • University of Iowa Health Care · Iowa City, United States
  • Vanderbilt University Medical Center · Nashville, United States
  • Klinik und Poliklinik für Urologie, TUM Klinikum · München, Germany
  • Universitätsklinikum Ulm, Klinik für Urologie und Kinderurologie · Ulm, Germany
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    4 sites added. Marien Hospital Herne, Universitätsklinikum der Ruhr-Universität Bochum is now Recruiting
    Show 4 added (2 United States, 2 Germany)
    • University of Iowa Health Care · Iowa City, United States
    • Vanderbilt University Medical Center · Nashville, United States
    • Klinik und Poliklinik für Urologie, TUM Klinikum · München, Germany
    • Universitätsklinikum Ulm, Klinik für Urologie und Kinderurologie · Ulm, Germany

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07144319
Lead sponsor
Photocure
Responsible party
Sponsor
First posted
Aug 27, 2025
Start date
Mar 25, 2026
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Kristine Young-Halvorsen, PhD
Contact
research@photocure.com
004722062210

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion